Arcturus Therapeutics

Arcturus Therapeutics is a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases
image_banner
VideoScaler
Cystic Fibrosis
Arcalis
STARR® Technology
LUNAR® Mechanism of Delivery
Cystic Fibrosis
Arcalis
STARR® Technology
LUNAR® Mechanism of Delivery
Cystic Fibrosis
Arcalis
STARR® Technology
LUNAR® Mechanism of Delivery
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://arcturusrx.com/wp-content/uploads/2023/01/JoePayne_LanguageProficiency_V3_1.mp4,GqH6_3YbPE8
arabic
(عربى)
https://arcturusrx.com/wp-content/uploads/2023/01/MaherA_LanguageProficiency_V3_1.mp4,5UG1sJAhn9c
chinese
(中文)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_BelleBao.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/BelleBao_LanguageProficiency__V3_1.mp4,AYmnmwhc4Sk
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_HowardYu.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/HowardYu_LanguageProficiency_V3_1.mp4,Y1CtyRPFaX0
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_YurongGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/YurongGuo_LanguageProficiency_V3_1.mp4,C2b3_eHyRhU
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_XuefengGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/XuefengGuo_LanguageProficiency_V3_1.mp4,2xl9qMbKY7E
english
(British)
https://arcturusrx.com/wp-content/uploads/2023/01/MikeHodges_LanguageProficiency_V3_1.mp4,I3h8XBCkHNw
farsi
(فارسی)
https://arcturusrx.com/wp-content/uploads/2023/01/NedaSafarzadeh_LanguageProficiency_V5.mp4,icGbloTCg7U
french
(Français)
https://arcturusrx.com/wp-content/uploads/2023/01/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4,82m_php4iVY
german
(deutsch)
https://arcturusrx.com/wp-content/uploads/2023/01/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4,LtWT-TiVJDE
hebrew
(עִברִית)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_NoaScott.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/NoaScott_LanguageProficiency_V3_1.mp4,rY5LNfJEDT8
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_TamarGrossman.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/TamarGrossman_LanguageProficiency_V3_1.mp4,3Yx6MAJaQwE
hindi
(हिन्दी)
https://arcturusrx.com/wp-content/uploads/2023/01/PriyaKarmali_LanguageProficiency_V3_1.mp4,JkcPJYFUTw8
italian
(italiano)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_CristianoSacchetti.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/CristianoSacchetti_LanguageProficiency_V3_1.mp4,z0MvPIms_oc
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_GiulioCattarossi.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/GiulioCattarossi_LanguageProficiency_V3_1.mp4,tR0Jm6TfJd0
Japanese
(日本語)
https://arcturusrx.com/wp-content/uploads/2023/01/Kiyoshi_Tachikawa_v2.mp4,IOChrMthw7s
korean
(한국어)
https://arcturusrx.com/wp-content/uploads/2023/01/JaeHeonKim_LanguageProficiency_V3_1.mp4,_tAwdiqPqUk
portuguese
(Português)
https://arcturusrx.com/wp-content/uploads/2023/01/RamonDiazTrelles_LanguageProficiency_V3_1.mp4,nZGMDeB9DMo
spanish
(español)
https://arcturusrx.com/wp-content/uploads/2023/01/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4,UacjnjowMyQ
vietnamese
(Tiếng Việt)
https://arcturusrx.com/wp-content/uploads/2023/01/HannahHuynh_LanguageProficiency_V3_1.mp4,J4A2Qf6T4OE

Clinical Trials

LunairCF is a clinical trial investigating the use of mRNA therapy (also known as ARCT-032) as an alternative to treat Cystic Fibrosis.
LEARN MORE
The mRNA in LUNAR-OTC (also known as ARCT-810) is designed to be a template for making OTC enzyme. Arcturus uses its lipid nanoparticle technology, called LUNAR® to deliver the mRNA template for OTC to the liver, the place where the OTC enzyme is made.
LEARN MORE

News & Events

August 11, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
July 24, 2025
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
July 23, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
June 30, 2025
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
June 23, 2025
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
May 29, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
May 12, 2025
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
April 22, 2025
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
April 10, 2025
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
March 6, 2025
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
March 5, 2025
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
February 24, 2025
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
February 14, 2025
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 4, 2025
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
January 31, 2025
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
January 30, 2025
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
January 10, 2025
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
January 6, 2025
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
December 16, 2024
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
November 26, 2024
Arcturus Therapeutics to Attend Upcoming Investor Conferences

STARR® Technology

VideoScaler

LUNAR® Mechanism of Delivery

VideoScaler